CVS’s health services segment includes CVS Caremark, but the company would not break out the revenue the PBM business only.
Formulary Watch
Latest News
All News
Advertisement
Trial results showed that the combination of Lonsurf and bevacizumab provided improvements in overall survival.
The Association for Accessible Medicines (AAM) published a white paper on the impact that ongoing drug shortages have had on the generic and biosimilar industries, as well as possible solutions stakeholders can put into action.
Breyna is indicated for patients with asthma six years of age and as maintenance therapy for people with COPD.
Jemperli is the first immuno-oncology treatment approved in the frontline setting for patients with advanced or recurrent endometrial cancer.
For Magellan’s clients, Ozempic had the highest trend of any product in 2022, and Wegovy was the fifth highest drug in terms of trend. Diabetes as a whole is expected to become the top condition leading pharmacy trend by 2024.
Rezzayo is a novel once-weekly antifungal to treat invasive candidiasis, a serious infection that can affect the blood, heart and brain. It will have a wholesale acquisition cost of $1,950 per vial.
The FDA is requiring Citius Pharmaceuticals to do enhanced product testing for Lymphir (formerly I/Ontak) to treat patients with cutaneous T-cell lymphoma.
One of the two recalled lots of the birth control tested high for a known impurity.
Advertisement
Harm Reduction Therapeutics will supply at least 200,000 free doses of RiVive to communities that need it most.
The supply of fentanyl, epinephrine injection, and heparin, however, have been impacted by the July 19 tornado at Pfizer's North Carolina facility.
MacKay Jimeson of the advocacy organization Patients Rising talks about CMS’ decision to limit coverage for Alzheimer’s drugs to those with full approval.
Accountable care organizations (ACOs) use digital health to complement traditional resources.
Renee Rayburg talks about the specialty drug spend, which grew 14.1% in 2022. PSG analysts predict increases will continue to be in the low double-digits for the next three years.
Xdemvy is the first treatment that directly targets the mites involved in the Demodex blepharitis. It is expected to be available by the end of August 2023 and will have a list price of $1,850 per prescription.
If approved, Ofev would be the first approved treatment for children and adolescents with fibrosing interstitial lung disease. A decision is expected in the fourth quarter of this year.
Ycanth, a topical treatment for molluscum contagiosum, will be available in September. Pricing information has not yet been released.
Sara Izadi, Pharm.D., of Capital Rx, talks about Rx Reverse, an integrated clinical program designed to help members reverse diabetes and fight obesity.
Emergent BioSolutions has been providing the Cyfendus vaccine to the U.S. Department of Health and Human Services since 2019, under a pre-emergency use authorization status.
Vanflyta is the first FLT3 inhibitor approved to treat patients with newly diagnosed acute myeloid leukemia across three phases of treatment. It has a list price of $199,290 annually.
The FTC says that prior statements and studies about the PBM industry no longer reflect current market realities.
An analysis by Biosimilars Council has found that the reference product Lantus accounts for 54% of new prescriptions and is 78% of total market volume but demand for the unbranded interchangeable insulin glargine is increasing.
The newly formed Peterson Health Technology Institute was launched with $50 million to analyze clinical benefits and economic impact of new health technologies.
About 36% of Medicare Part D enrollees will benefit from the Inflation Reduction Act’s out-of-pocket caps for prescription drugs, which will go into effect in 2025.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Biosimilar competition could surpass IRA-negotiated savings by year three
4
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
5
